Precision BioSciences, Inc. (NASDAQ:DTIL) CEO Michael Amoroso Sells 1,526 Shares

Precision BioSciences, Inc. (NASDAQ:DTIL) CEO Michael Amoroso sold 1,526 shares of the business’s stock in a transaction on Thursday, May 2nd. The shares were sold at an average price of $10.32, for a total transaction of $15,748.32. Following the transaction, the chief executive officer now owns 13,772 shares of the company’s stock, valued at $142,127.04. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Precision BioSciences Stock Performance

Precision BioSciences stock opened at $10.52 on Monday. The company’s fifty day moving average price is $12.55 and its 200 day moving average price is $11.82. The stock has a market capitalization of $72.76 million, a P/E ratio of -0.65 and a beta of 1.62. Precision BioSciences, Inc. has a 1 year low of $8.25 and a 1 year high of $27.02.

Precision BioSciences (NASDAQ:DTIL) last released its earnings results on Wednesday, March 27th. The company reported ($3.35) EPS for the quarter, missing analysts’ consensus estimates of $3.00 by ($6.35). The company had revenue of $7.04 million for the quarter, compared to analysts’ expectations of $28.50 million. Precision BioSciences had a negative return on equity of 204.66% and a negative net margin of 125.84%. Sell-side analysts predict that Precision BioSciences, Inc. will post -3.93 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the company. Guggenheim assumed coverage on Precision BioSciences in a research note on Tuesday, April 30th. They issued a “buy” rating and a $19.00 target price on the stock. HC Wainwright reaffirmed a “buy” rating and set a $60.00 target price on shares of Precision BioSciences in a report on Wednesday, April 17th.

Institutional Investors Weigh In On Precision BioSciences

Hedge funds have recently modified their holdings of the company. Curi Wealth Management LLC raised its stake in shares of Precision BioSciences by 42.0% in the 3rd quarter. Curi Wealth Management LLC now owns 339,801 shares of the company’s stock valued at $116,000 after acquiring an additional 100,530 shares during the period. Tejara Capital Ltd lifted its stake in Precision BioSciences by 100.7% during the 3rd quarter. Tejara Capital Ltd now owns 398,614 shares of the company’s stock worth $136,000 after acquiring an additional 200,000 shares in the last quarter. Finally, Acadian Asset Management LLC boosted its holdings in Precision BioSciences by 8.3% during the 3rd quarter. Acadian Asset Management LLC now owns 3,148,243 shares of the company’s stock valued at $1,073,000 after acquiring an additional 242,425 shares during the period. Hedge funds and other institutional investors own 37.99% of the company’s stock.

Precision BioSciences Company Profile

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.